Non-canonical roles of PFKFB3 in regulation of cell cycle through binding to CDK4

Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma

(2017) Hui-Min Li et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

IKKβ promotes metabolic adaptation to glutamine deprivation via phosphorylation and inhibition of PFKFB3

(2016) Michael A. Reid et al.   GENES & DEVELOPMENT

Treating cancer with selective CDK4/6 inhibitors

(2016) Ben O'Leary et al.   Nature Reviews Clinical Oncology

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

(2016) C Yang et al.   ONCOGENE

Atomic structure of Hsp90-Cdc37-Cdk4 reveals that Hsp90 traps and stabilizes an unfolded kinase

(2016) K. A. Verba et al.   SCIENCE

Aerobic glycolysis tunes YAP/TAZ transcriptional activity

(2015) E. Enzo et al.   EMBO JOURNAL

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer

(2015) Janice Lu   Journal of Hematology & Oncology

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest

(2015) Elena Doménech et al.   NATURE CELL BIOLOGY

The history and future of targeting cyclin-dependent kinases in cancer therapy

(2015) Uzma Asghar et al.   NATURE REVIEWS DRUG DISCOVERY

p54nrb/NONO regulates lipid metabolism and breast cancer growth through SREBP-1A

(2015) Z Zhu et al.   ONCOGENE

Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA

(2015) Marco Perez et al.   Oncotarget

The expression pattern of PFKFB3 enzyme distinguishes between induced-pluripotent stem cells and cancer stem cells

(2015) Artur Cieślar-Pobuda et al.   Oncotarget

CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers

(2014) A. M. Heilmann et al.   CANCER RESEARCH

Formononetin Promotes Cell Cycle Arrest via Downregulation of Akt/Cyclin D1/CDK4 in Human Prostate Cancer Cells

(2014) Tianyu Li et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Estradiol Stimulates Glucose Metabolism via 6-Phosphofructo-2-kinase (PFKFB3)

(2014) Yoannis Imbert-Fernandez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Synthetic Lethal Therapy for KRAS Mutant Non-small-cell Lung Carcinoma with Nanoparticle-mediated CDK4 siRNA Delivery

(2014) Cheng-Qiong Mao et al.   MOLECULAR THERAPY

MEN1 tumorigenesis in the pituitary and pancreatic islet requires Cdk4 but not Cdk2

(2014) M P Gillam et al.   ONCOGENE

CDK2 and CDK4 play important roles in promoting the proliferation of SKOV3 ovarian carcinoma cells induced by tumor-associated macrophages

(2014) YANG YANG et al.   ONCOLOGY REPORTS

Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

(2014) Richard J. Young et al.   Pigment Cell & Melanoma Research

6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27

(2014) A Yalcin et al.   Cell Death & Disease

Partial and Transient Reduction of Glycolysis by PFKFB3 Blockade Reduces Pathological Angiogenesis

(2013) Sandra Schoors et al.   Cell Metabolism

Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer

(2013) B. F. Clem et al.   MOLECULAR CANCER THERAPEUTICS

PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis

(2012) Weiwei Yang et al.   CELL

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

(2012) Patrick J. Roberts et al.   JNCI-Journal of the National Cancer Institute

p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells

(2012) L. Cen et al.   NEURO-ONCOLOGY

Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression

(2011) Yoshiki Katsumi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

(2011) Gottfried E. Konecny et al.   CLINICAL CANCER RESEARCH

Molecular basis of the fructose-2,6-bisphosphatase reaction of PFKFB3: Transition state and the C-terminal function

(2011) Michael C. Cavalier et al.   PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

Cyclin D1/Cyclin-Dependent Kinase 4 Interacts with Filamin A and Affects the Migration and Invasion Potential of Breast Cancer Cells

(2010) Z. Zhong et al.   CANCER RESEARCH

STAT1 interacts directly with cyclin D1/Cdk4 and mediates cell cycle arrest

(2010) Gloria Dimco et al.   CELL CYCLE

Downregulation of MSP58 inhibits growth of human colorectal cancer cells via regulation of the cyclin D1-cyclin-dependent kinase 4-p21 pathway

(2009) Hai Shi et al.   CANCER SCIENCE

Nuclear Targeting of 6-Phosphofructo-2-kinase (PFKFB3) Increases Proliferation via Cyclin-dependent Kinases

(2009) Abdullah Yalcin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Hsp90-Dependent Activation of Protein Kinases Is Regulated by Chaperone-Targeted Dephosphorylation of Cdc37

(2008) Cara K. Vaughan et al.   MOLECULAR CELL

Cyclin-dependent kinase 4/6 activity is a critical determinant of pre-replication complex assembly

(2008) W A Braden et al.   ONCOGENE

Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors

(2008) J R Smith et al.   ONCOGENE